

Cellnovo Strengthens Board by appointing Rémi Soula as a Non-Executive Director

Paris, France, September 26, 2016 - Cellnovo Group ("Cellnovo" CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, is pleased to announce the appointment of Rémi Soula as a Non-Executive Director.

Rémi Soula has extensive experience in the French medical technology and biotechnology sector and is one of the three founders of Adocia, a clinical-stage biotechnology company with one of the largest and most differentiated insulin formulation portfolios in the industry. M Soula is currently the Director of Business Development and Intellectual Property Director at Adocia and has co-authored more than 30 patents and six scientific publications. Prior to this, M Soula spent three years at Flamel Technologies as Senior Chemist in Polymer Synthesis. M Soula holds a PhD in Polymer Science, a Post-doctorate from the Max Planck Institute in Potsdam and an MBA from HEC Paris.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: *"I am delighted to welcome Rémi Soula as a Non-Executive Director to the Board. Rémi's interactions within the insulin industry will help us to execute on our strategic roadmap and his skills lend themselves strongly to Cellnovo. Rémi's experience in the field of diabetes treatment, particularly in the innovative formulations of insulin, is highly applicable to Cellnovo and will prove invaluable as we continue with the international commercialisation of our diabetes management system and progression of our Artificial Pancreas program."*

Rémi Soula, Non-Executive Director of Cellnovo, said: *"It is a great pleasure to be joining Cellnovo at such a pivotal time for the Company. I look forward to working with the Board and the wider team on the next phase of growth for Cellnovo's mobile, connected, all-in-one diabetes management system as well as becoming involved with the ambitious work the Company is undertaking in the development of an Artificial Pancreas."*

●●●

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.



The First Connected All-in-one Diabetes Management System

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Chris Gardner, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

